Study · Not a test of the peptide alone · 2009

6 results

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.

Rother KI, Spain LM, Wesley RA, Digon BJ 3rd, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM

Diabetes care6 Oct 2009Cited by 103 (Europe PMC)

PMID19808924PMCIDPMC2782986DOI10.2337/dc09-0773PepBankPUB-19808924

Read at source PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In long-standing type 1 diabetes, exenatide regimens with or without daclizumab were associated with body weight loss.
In plain wordsIn long-standing type 1 diabetes, patients lost weight during exenatide regimens with or without daclizumab.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 16
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight loss
4.1 kg
during exenatide treatment (SD 2.9)
Source sentences
Summary
During exenatide treatment, patients lost 4.1 +/- 2.9 kg body wt and insulin requirements declined significantly (total daily dose on exenatide 0.48 +/- 0.11 vs. 0.55 +/- 0.13 units x kg(-1) x day(-1) without exenatide; P = 0.0062).
2 context sentences(design, population, supporting numbers)
Summary · context
For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial.
Summary · context
After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1980892401
02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In long-standing type 1 diabetes, insulin requirements declined during exenatide regimens with or without daclizumab versus without exenatide.
In plain wordsPatients needed less insulin during exenatide regimens with or without daclizumab than without exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInsulin requirements
Study
n = 16
Comparator
Without exenatide
Outcome group
Glycemic control · Metabolic and weight
Measurements
Total daily insulin dose
0.48 units/kg/day
on exenatide (SD 0.11)
Total daily insulin dose
0.55 units/kg/day
without exenatide (SD 0.13)
Source sentences
Summary
During exenatide treatment, patients lost 4.1 +/- 2.9 kg body wt and insulin requirements declined significantly (total daily dose on exenatide 0.48 +/- 0.11 vs. 0.55 +/- 0.13 units x kg(-1) x day(-1) without exenatide; P = 0.0062).
2 context sentences(design, population, supporting numbers)
Summary · context
For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial.
Summary · context
After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1980892402
03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In long-standing type 1 diabetes, exenatide regimens with or without daclizumab showed no further autoimmune activation.
In plain wordsPatients showed no further autoimmune activation during exenatide regimens with or without daclizumab.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAutoimmune activation
Study
n = 16
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
No signs of further activation of the underlying autoimmune disease were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial.
Summary · context
After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1980892403
04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In long-standing type 1 diabetes, exenatide regimens with or without daclizumab delayed gastric emptying.
In plain wordsExenatide regimens with or without daclizumab delayed stomach emptying in patients with long-standing type 1 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGastric emptying
Study
n = 16
Outcome group
Gastrointestinal motility · Gastrointestinal
Source sentences
Summary
Exenatide delayed gastric emptying, suppressed endogenous incretin levels, but did not increase C-peptide secretion.
2 context sentences(design, population, supporting numbers)
Summary · context
For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial.
Summary · context
After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1980892404
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In long-standing type 1 diabetes, exenatide regimens with or without daclizumab suppressed endogenous incretin levels.
In plain wordsExenatide regimens with or without daclizumab lowered natural incretin levels in patients with long-standing type 1 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseEndogenous incretin levels
Study
n = 16
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Exenatide delayed gastric emptying, suppressed endogenous incretin levels, but did not increase C-peptide secretion.
2 context sentences(design, population, supporting numbers)
Summary · context
For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial.
Summary · context
After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1980892405
06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In long-standing type 1 diabetes, exenatide regimens with or without daclizumab did not increase C-peptide secretion.
In plain wordsExenatide regimens with or without daclizumab did not increase C-peptide secretion in patients with long-standing type 1 diabetes.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeC-peptide secretion
Study
n = 16
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Exenatide delayed gastric emptying, suppressed endogenous incretin levels, but did not increase C-peptide secretion.
2 context sentences(design, population, supporting numbers)
Summary · context
For this study, 20 individuals (mean age 39.5 +/- 11.1 years) with long-standing type 1 diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial.
Summary · context
After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or without daclizumab.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1980892406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01722266

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

University at Buffalon = 721 Nov 2012 to 1 Dec 2014

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 5 Jan 2024

CompletedPhase 2NCT00064714

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

AstraZenecan = 47Jul 2003 to Mar 2008

Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 11 Mar 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.